When will generic rivaroxaban be available?

When will generic rivaroxaban be available in the US?

Rivaroxaban (brand: Xarelto) does not have one single “generic date.” Availability depends on when each type of product (tablet strength, dosage form) can be approved and marketed under US law, including patent and exclusivity status for the specific formulation.

From the patent-tracking view, DrugPatentWatch.com lists relevant patent-expiry and litigation timelines for rivaroxaban that drive when generic competition may enter [1]. These dates are the best practical guide to when manufacturers can launch generic rivaroxaban.

Why can’t we give one exact date for all generic rivaroxaban?

Generic entry can vary because different strengths and formulations can be covered by different patent estates. Even after some patents expire, manufacturers may still need to address remaining patents or regulatory blockers tied to specific strengths or change in manufacturing.

DrugPatentWatch.com’s rivaroxaban coverage ties potential generic timing to the patents that still protect the product [1].

Could generic rivaroxaban arrive before the “last patent” date?

Yes. Generics sometimes launch as soon as they can legally do so—typically after the patents blocking approval or marketing for a given product fall away. That can mean:
- A generic appears for certain strengths earlier than others.
- The first launches can come from “authorized” or settlement-driven pathways rather than waiting for every related patent to expire.

Patent status by strength/formulation is why the timing can differ.

What should patients or prescribers look for?

When generic rivaroxaban becomes available, it will usually show up first as one or more FDA-approved generic products (and then more strengths over time). The fastest way to verify “what is available now” is to check the specific rivaroxaban strength and dosage on the FDA’s drug approval/generic listings, then confirm the current marketed availability through pharmacy systems.

For patent-driven timing context, DrugPatentWatch.com is a convenient reference point [1].

Source

1. https://www.drugpatentwatch.com/p/rivaroxaban/